Loss of PTEN Expression, PIK3CA Mutations, and Breast Cancer Survival in the Nurses' Health Studies.
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
04 10 2022
04 10 2022
Historique:
received:
11
06
2022
revised:
28
06
2022
accepted:
29
07
2022
pubmed:
2
8
2022
medline:
6
10
2022
entrez:
1
8
2022
Statut:
ppublish
Résumé
The relationships between PTEN loss and/or PIK3CA mutation and breast cancer prognosis remain controversial. We aim to examine the associations in large epidemiologic cohorts. We followed women with invasive breast cancer from the Nurses' Health Studies with available data on tumor PTEN expression (n = 4,111) and PIK3CA mutation (n = 2,930). PTEN expression was evaluated by IHC and digitally scored (0%-100%). Pyrosequencing of six hotspot mutations of PIK3CA was performed. We found loss of PTEN expression (≤10%) occurred in 17% of cases, and PIK3CA mutations were detected in 11% of cases. After adjusting for clinical and lifestyle factors, PTEN loss was not associated with worse breast cancer-specific mortality among all samples [HR, 0.85; 95% confidence intervals (CI), 0.71-1.03] or among estrogen receptor (ER)-positive tumors (HR, 0.99; 95% CI, 0.79-1.24). However, among ER-negative tumors, PTEN loss was associated with lower breast cancer-specific mortality (HR, 0.68; 95% CI, 0.48-0.95). PIK3CA mutation was not strongly associated with breast cancer-specific mortality (HR, 0.89; 95% CI, 0.67-1.17). Compared with tumors without PTEN loss and without PIK3CA mutation, those with alterations (n = 540) were not at higher risk (HR, 1.07; 95% CI, 0.86-1.34). However, women with both PTEN loss and PIK3CA mutation (n = 38) were at an increased risk of breast cancer-specific mortality (HR, 1.65; 95% CI, 0.83-3.26). In this large epidemiologic study, the PTEN-mortality association was more pronounced for ER-negative tumors, and the joint PTEN loss and PIK3CA mutation may be associated with worse prognosis. Further studies with a larger sample of ER-negative tumors are needed to replicate our findings and elucidate underlying mechanisms.
Sections du résumé
BACKGROUND
The relationships between PTEN loss and/or PIK3CA mutation and breast cancer prognosis remain controversial. We aim to examine the associations in large epidemiologic cohorts.
METHODS
We followed women with invasive breast cancer from the Nurses' Health Studies with available data on tumor PTEN expression (n = 4,111) and PIK3CA mutation (n = 2,930). PTEN expression was evaluated by IHC and digitally scored (0%-100%). Pyrosequencing of six hotspot mutations of PIK3CA was performed.
RESULTS
We found loss of PTEN expression (≤10%) occurred in 17% of cases, and PIK3CA mutations were detected in 11% of cases. After adjusting for clinical and lifestyle factors, PTEN loss was not associated with worse breast cancer-specific mortality among all samples [HR, 0.85; 95% confidence intervals (CI), 0.71-1.03] or among estrogen receptor (ER)-positive tumors (HR, 0.99; 95% CI, 0.79-1.24). However, among ER-negative tumors, PTEN loss was associated with lower breast cancer-specific mortality (HR, 0.68; 95% CI, 0.48-0.95). PIK3CA mutation was not strongly associated with breast cancer-specific mortality (HR, 0.89; 95% CI, 0.67-1.17). Compared with tumors without PTEN loss and without PIK3CA mutation, those with alterations (n = 540) were not at higher risk (HR, 1.07; 95% CI, 0.86-1.34). However, women with both PTEN loss and PIK3CA mutation (n = 38) were at an increased risk of breast cancer-specific mortality (HR, 1.65; 95% CI, 0.83-3.26).
CONCLUSIONS
In this large epidemiologic study, the PTEN-mortality association was more pronounced for ER-negative tumors, and the joint PTEN loss and PIK3CA mutation may be associated with worse prognosis.
IMPACT
Further studies with a larger sample of ER-negative tumors are needed to replicate our findings and elucidate underlying mechanisms.
Identifiants
pubmed: 35914729
pii: 707366
doi: 10.1158/1055-9965.EPI-22-0672
pmc: PMC9532372
mid: NIHMS1828974
doi:
Substances chimiques
Receptors, Estrogen
0
Class I Phosphatidylinositol 3-Kinases
EC 2.7.1.137
PIK3CA protein, human
EC 2.7.1.137
PTEN Phosphohydrolase
EC 3.1.3.67
PTEN protein, human
EC 3.1.3.67
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1926-1934Subventions
Organisme : NCI NIH HHS
ID : R01 CA050385
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA087969
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA207369
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA176726
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA186107
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009001
Pays : United States
Informations de copyright
©2022 American Association for Cancer Research.
Références
Chin J Cancer. 2012 Jul;31(7):327-34
pubmed: 22640628
Proc Natl Acad Sci U S A. 2007 May 1;104(18):7564-9
pubmed: 17452630
Cancer Cell. 2007 Oct;12(4):395-402
pubmed: 17936563
Mol Med Rep. 2017 May;15(5):2957-2968
pubmed: 28358430
NPJ Breast Cancer. 2018 Oct 12;4:34
pubmed: 30345349
Oncotarget. 2017 May 9;8(19):32043-32054
pubmed: 28410191
Am J Epidemiol. 1984 May;119(5):837-9
pubmed: 6720679
Crit Rev Oncol Hematol. 2016 May;101:40-9
pubmed: 26951995
Breast Cancer Res. 2008;10(4):R67
pubmed: 18681955
Med Oncol. 2014 Jan;31(1):801
pubmed: 24326984
Cancer Cell. 2005 Jun;7(6):561-73
pubmed: 15950905
Strahlenther Onkol. 2014 Jul;190(7):636-8, 640-5
pubmed: 24658605
Cancer Genomics Proteomics. 2019 May-Jun;16(3):195-206
pubmed: 31018950
Breast Cancer Res. 2020 May 13;22(1):45
pubmed: 32404150
Cancer Res. 2005 Jun 1;65(11):4562-7
pubmed: 15930273
Clin Cancer Res. 2015 May 1;21(9):2065-74
pubmed: 25649019
Breast Cancer Res Treat. 2008 Aug;110(3):477-83
pubmed: 17805960
J Natl Cancer Inst. 2019 Jul 1;111(7):700-708
pubmed: 30445651
Ann Oncol. 2020 Mar;31(3):377-386
pubmed: 32067679
Am J Epidemiol. 2008 Mar 15;167(6):653-66
pubmed: 18230679
Annu Rev Pathol. 2009;4:127-50
pubmed: 18767981
Oncogene. 2011 Oct 20;30(42):4327-38
pubmed: 21532617
Breast Cancer Res. 2012 Feb 13;14(1):R28
pubmed: 22330809
NPJ Breast Cancer. 2020 Sep 25;6:47
pubmed: 33062889
Nat Rev Cancer. 2002 Jul;2(7):489-501
pubmed: 12094235
J Clin Oncol. 2018 Apr 1;36(10):981-990
pubmed: 29470143
Cancer Res. 2007 Jun 15;67(12):5851-8
pubmed: 17575153
Postepy Hig Med Dosw (Online). 2015 May 05;69:586-97
pubmed: 25983297
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Asian Pac J Cancer Prev. 2019 Jan 25;20(1):269-276
pubmed: 30678449
Cancer Res. 2021 Aug 1;81(15):4155-4162
pubmed: 34108141
J Clin Oncol. 2013 Jun 10;31(17):2115-22
pubmed: 23650412
J Pathol. 2017 Feb;241(3):375-391
pubmed: 27861902
Cancer Epidemiol. 2021 Oct;74:101999
pubmed: 34352659
In Vivo. 2018 Mar-Apr;32(2):303-311
pubmed: 29475913
J Natl Cancer Inst. 1998 Aug 5;90(15):1155-60
pubmed: 9701365
Nat Rev Cancer. 2005 May;5(5):388-96
pubmed: 15864280
Hum Pathol. 2009 Oct;40(10):1408-17
pubmed: 19428048
Asian Pac J Cancer Prev. ;17(9):4527-4531
pubmed: 27912236
Histopathology. 2012 Oct;61(4):652-9
pubmed: 22759273
Cell Death Dis. 2020 Nov 21;11(11):1001
pubmed: 33221821
Int J Cancer. 2010 Mar 1;126(5):1121-31
pubmed: 19685490
J Natl Cancer Inst. 2013 Jul 3;105(13):960-7
pubmed: 23739063
PLoS One. 2018 Sep 13;13(9):e0203495
pubmed: 30212483
JAMA Oncol. 2016 Dec 01;2(12):1565-1573
pubmed: 27388585
Breast Cancer Res Treat. 2015 Jun;151(3):541-53
pubmed: 25981902
Hum Pathol. 2017 Mar;61:49-57
pubmed: 27864123
Trends Cancer. 2016 Jan;2(1):35-48
pubmed: 28741499
Nat Rev Mol Cell Biol. 2012 Apr 04;13(5):283-96
pubmed: 22473468
Cancer Res. 2005 Apr 1;65(7):2554-9
pubmed: 15805248
Sci Rep. 2014 Sep 01;4:6255
pubmed: 25176561